NEW YORK CITY, NY / ACCESS Newswire / July 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR). Investors who purchased Capricor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CAPR.

Investigation Details

On May 5, 2025, Capricor issued a press release announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. On this news, Capricor's stock price fell $3.00 per share, or 29.13%, to close at $7.30 per share on May 6, 2025. Then, on June 20, 2025 the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug's efficacy and safety. On this news, Capricor's stock price fell $3.68 per share, or 30.82%, to close at $8.26 per share on June 20, 2025.

What's Next?

If you are aware of any facts relating to this investigation or purchased Capricor securities, you can assist this investigation by visiting the firm's site: bgandg.com/CAPR. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACTBronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

COMTEX_467105846/2457/2025-07-08T10:01:51